Stocktoria
Pyxis Oncology, Inc. PYXS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-10-08
Chart by TradingView
2/9
Piotroski F — financial health
-16.86
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $13.9M | $16.1M | — | — | — |
| Operating income | -$84.4M | -$89.5M | -$82.2M | -$123.5M | -$69.7M |
| Net income | -$79.6M | -$77.3M | -$73.8M | -$120.7M | -$76.0M |
| Operating cash flow | -$63.5M | -$57.7M | -$70.7M | -$89.3M | -$35.3M |
| Free cash flow | -$63.5M | -$57.9M | -$77.4M | -$95.7M | -$35.9M |
| Total assets | $91.5M | $157.2M | $173.7M | $211.4M | $280.0M |
| Total liabilities | $38.1M | $36.4M | $48.0M | $50.6M | $18.7M |
| Shareholders' equity | $53.4M | $120.8M | $125.7M | $160.8M | $261.3M |
| Ratios | |||||
| Operating margin | -609.2% | -554.1% | — | — | — |
| Net margin | -574.5% | -478.9% | — | — | — |
| FCF margin | -458.3% | -358.7% | — | — | — |
| Return on assets | -87.0% | -49.2% | -42.5% | -57.1% | -27.1% |
| Return on equity | -149.1% | -64.0% | -58.7% | -75.1% | -29.1% |
| Current ratio | 3.41 | 7.49 | 4.84 | 5.90 | 14.90 |
| Revenue growth | -14.2% | — | — | — | — |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 888,680 | $1.3M |
| Point72 Asset Management, L.P. | 32,006 | $46,729 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -16.86 (distress)
- Working capital / assets 0.557
- Retained earnings / assets -4.842
- EBIT / assets -0.922
- Equity / liabilities 1.401
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001782223 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.